Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis

Abstract Background The oral anti‐janus kinase 1 inhibitor upadacitinib has shown a good efficacy–safety profile in the treatment of moderate‐to‐severe atopic dermatitis (AD) in clinical trials; however, few data from real clinical practice have been published so far. Objectives To evaluate the effi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ana Batalla, Hae Jin Suh‐Oh, Gregorio Carretero Hernández, Javier Miquel‐Miquel, Rafael Botella‐Estrada, Antonio Martorell‐Calatayud, Virginia Sanz‐Motilva, Ignasi Figueras‐Nart, Angeles Flórez
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Wiley 2023-09-01
Saila:	JEADV Clinical Practice
Gaiak:	atopic dermatitis treatment upadacitinib
Sarrera elektronikoa:	https://doi.org/10.1002/jvc2.179
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!